Selling as is to buyers who price certainty

An AI laboratory buying data and a bankruptcy estate selling it are, on paper, a poor match. The laboratory prices certainty. The estate sells as is, where is, with no representations and nobody left to make them. Every question the estate cannot answer becomes a discount, and enough of them become a pass. Closing that gap is the actual work of an estate data sale, and it starts with knowing what the diligence will ask.

It will ask about provenance first: where each record came from, under what terms, and whether the seller can show the chain rather than assert it. To a laboratory's counsel, a dataset with documented lineage and an identical dataset with murky lineage are different products at different prices. Estates start behind here, because the people who knew the lineage are gone. But lineage lives in contracts, policies, and system logs as much as in memory, and it can be reassembled.

It will ask about contamination next. Laboratories sample for personal information that should not be present, material copied from elsewhere, machine-generated content posing as human, and duplicates inflating the apparent size. They will run these tests regardless of what the seller claims. A seller who has run them first, and hands over the results, has replaced an unknown with a number. Replacing unknowns with numbers is precisely the trade laboratories pay for.

It will ask, without quite saying so, what the data costs to use. Two archives can hold the same information and differ enormously in price because one is organized and documented and the other is a heap. Laboratories have budget and no patience. Anything that shortens the path from delivery to training shows up in the offer.

And behind every question sits the one sellers cannot see: what the buyer already holds. A laboratory saturated with web text will pay nothing for more of it and a premium for what the open internet does not contain: clinical imaging, industrial telemetry, proprietary code, expert annotation. Distressed companies are disproportionately rich in exactly this kind of data. That is why an estate too small to interest any strategic acquirer can still interest a laboratory, and why placement is not a mailing list. The same archive is worthless to one lab and strategic to another, and knowing which is which is the seller's entire edge.

The encouraging part is that diligence questions are standard, which means their answers can be manufactured during the sale process: an inventory, a sampling report, a rights memo. As is, where is describes the estate's warranties. It does not have to describe its preparation. An estate that shows up with the answers written down has taken back most of the discount.